For HR+ HER2- BC seeking a second-line option, a targeted NGS BC panel is very useful to tell whether the tumor harbors an actionable mutation in critical BC-related genes, including ESR1, PIK3CA, AKT1, PTEN, as well as additional genes in the PI3K pathway or other synergetic pathways. This evidence concerns the gene ERBB2 and breast cancer.